PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (20)
2023
-
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Viruses, Vol. 15, Núm. 7
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
-
A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
European Journal of Internal Medicine, Vol. 78, pp. 41-49
-
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
-
SEOM clinical guideline in nasopharynx cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 84-88
2017
-
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009
-
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694
-
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome
PLoS ONE, Vol. 12, Núm. 11
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
-
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137
2015
-
Mammographic density and breast cancer in women from high risk families
Breast Cancer Research, Vol. 17, Núm. 1
-
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 10, pp. 763-771
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2012
-
Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739
-
Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia